Famotidine adjunctive pharmacotherapy of schizophrenia: A case report

R. B. Rosse, K. Kendrick, L. C. Tsui, M. Fay-McCarthy, J. P. Collins, P. Rosenberg, R. J. Wyatt, S. I. Deutsch

Research output: Contribution to journalArticlepeer-review


Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporally related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of ~10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo- controlled trials are needed to more fully evaluate the utility of famoditine in the treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalClinical neuropharmacology
Issue number4
StatePublished - Jan 1 1995
Externally publishedYes


  • Famotidine
  • H2 antagonist
  • H2 receptor
  • Histamine
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Famotidine adjunctive pharmacotherapy of schizophrenia: A case report'. Together they form a unique fingerprint.

Cite this